This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Anuh Pharma Limited has informed the Exchange regarding 'Financial Results'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma reported annual revenue of Rs 77,166 Lakhs for FY26, up 16.6% from Rs 66,151 Lakhs in FY25. However, profit after tax declined 13.3% to Rs 4,105 Lakhs from Rs 4,735 Lakhs due to higher input costs and raw material expenses. EBITDA margin compressed to 8.56% from 10.64% in the prior year. The company completed a 1:1 bonus share issuance in July 2025, doubling share capital to Rs 5,011 Lakhs. The board recommended a dividend of Rs 1.50 per share. Inventories nearly doubled to Rs 14,776 Lakhs while operating cash flow turned negative at Rs -301 Lakhs due to working capital buildup. Auditors issued an unqualified (clean) opinion.
While revenue growth demonstrates business expansion, the decline in profitability and margin compression signal cost pressures that concern investors. The sharp rise in inventory and negative operating cash flow may require monitoring. The clean audit opinion provides assurance on financial reporting quality.
| Q4 FY26 | Q4 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹202.1 Cr | ₹198.1 Cr | +2.0% |
| Operating profit | ₹16.77 Cr | ₹15.88 Cr | +5.6% |
| Profit after tax | ₹11.68 Cr | ₹12.46 Cr | −6.2% |
| EBITDA margin | 9.8% | 9.4% | +0.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.